BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported E.P.S. of $-0.07 for its third fiscal quarter (ending September 30) versus $-0.19 for the same period a year ago — a decline of -63%. For the latest four quarters through September 30, E.P.S. were $-0.61 versus $-1.25 for the same period a year ago — a decline of -51%.
Recent Price Action
On 11/4/24, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock suffered a major decline of -12.8%, closing at $7.35. Moreover, exceptionally high trading volume at 593% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -7.5% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.